Hrt Financial LP Humanigen, Inc Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.13 - $0.2 $1,253 - $1,927	-9,639 Reduced 36.92%	16,469 $2,000
Q1 2023 May 12, 2023	BUY	$0.12 - $0.23 $3,132 - $6,004	26,108 New	26,108 $3,000
Q2 2022 Aug 12, 2022	BUY	$1.76 - $3.33 $65,718 - $124,342	37,340 New	37,340 $66,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $774,904 - $1.7 Million	-428,124 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $1.57 Million - $3.52 Million	428,124 New	428,124 $1.59 Million
Q2 2021 Aug 16, 2021	SELL	$13.54 - $22.74 $2.2 Million - $3.69 Million	-162,373 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $2.1 Million - $3.87 Million	162,373 New	162,373 $3.1 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.